Common BPC-157 examples include 200 mcg, 250 mcg, 500 mcg, and 1000 mcg
Several well-established and widely prescribed GLP-1 receptor agonists, including various formulations of semaglutide, liraglutide, and dulaglutide, are administered via subcutaneous injection
Once tissues heal properly, they remain healed
However, pairing GLP-1 drugs with DPP-4 inhibitors is generally avoided since both act on the same pathway, resulting in overlapping effects without meaningful added benefits
Platforms like MeAgain centralize injection schedules, symptom and injection-site tracking, hydration and protein goals, and exportable timelines, giving clinicians a coherent dataset to act on and patients a simple way to show progress without repeating the same story at every visit
While compounding itself isnt illegal, applying it to GLP-1 agonists specifically ignites numerous concerns